Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-27
2009-10-20
Sullivan, Daniel M (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S374000, C514S375000, C514S381000, C514S386000, C514S406000, C514S414000, C514S233500, C514S254090, C514S256000, C514S365000, C514S339000, C514S345000, C544S058200, C544S143000, C544S333000, C544S373000, C546S016000, C546S201000, C546S277400, C546S115000
Reexamination Certificate
active
07605156
ABSTRACT:
This invention provides methods for the use of substituted indole compounds of the general formula:and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.
REFERENCES:
patent: 3505354 (1970-04-01), Doebel et al.
patent: 3629284 (1971-12-01), Yamamoto et al.
patent: 3931229 (1976-01-01), Zinnes et al.
patent: 4271263 (1981-06-01), Goettert
patent: 4654360 (1987-03-01), Greenhouse et al.
patent: 4774240 (1988-09-01), Boshagen et al.
patent: 4894386 (1990-01-01), Brown et al.
patent: 5081145 (1992-01-01), Guindon et al.
patent: 5166170 (1992-11-01), Tegeler et al.
patent: 5190968 (1993-03-01), Gillard et al.
patent: 5206377 (1993-04-01), McAfee
patent: 5212195 (1993-05-01), Clark et al.
patent: 5229516 (1993-07-01), Musser et al.
patent: 5288743 (1994-02-01), Brooks et al.
patent: 5290798 (1994-03-01), Guillard et al.
patent: 5314908 (1994-05-01), McAfee
patent: 5322776 (1994-06-01), Knopf et al.
patent: 5332755 (1994-07-01), Butler et al.
patent: 5354677 (1994-10-01), Knopf et al.
patent: 5380739 (1995-01-01), Clark et al.
patent: 5420289 (1995-05-01), Musser et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 5482960 (1996-01-01), Berryman et al.
patent: 5641800 (1997-06-01), Bach et al.
patent: 5686481 (1997-11-01), Elliott et al.
patent: 6500853 (2002-12-01), Seehra et al.
patent: 6630496 (2003-10-01), Seehra et al.
patent: 6635771 (2003-10-01), McKew et al.
patent: 6797708 (2004-09-01), McKew et al.
patent: 6891065 (2005-05-01), Wu et al.
patent: 6984735 (2006-01-01), McKew et al.
patent: 2003/0144282 (2003-07-01), McKew et al.
patent: 2003/0149209 (2003-08-01), Inagaki et al.
patent: 2004/0186116 (2004-09-01), Saunders et al.
patent: 2005/0049296 (2005-03-01), Dehnhardt et al.
patent: 2005/0053600 (2005-03-01), Lane
patent: 2005/0070723 (2005-03-01), Dehnhardt et al.
patent: 2005/0148770 (2005-07-01), Michalak et al.
patent: 2005/0159613 (2005-07-01), Wu et al.
patent: 2006/0014759 (2006-01-01), McKew et al.
patent: 2006/0041005 (2006-02-01), Michalak et al.
patent: 2007/0004719 (2007-01-01), McKew et al.
patent: 484111 (1970-01-01), None
patent: 1816335 (1970-07-01), None
patent: 4338770 (1995-05-01), None
patent: 0337766 (1989-10-01), None
patent: 0337767 (1989-10-01), None
patent: 0535923 (1993-04-01), None
patent: 535926 (1993-04-01), None
patent: 549916 (1993-07-01), None
patent: 549916 (1993-07-01), None
patent: 676959 (1994-07-01), None
patent: 0620215 (1994-10-01), None
patent: 922028 (1998-03-01), None
patent: 1583747 (2004-07-01), None
patent: 1648861 (2005-02-01), None
patent: 1697320 (2005-06-01), None
patent: 1492929 (1967-07-01), None
patent: WO 91/06537 (1991-05-01), None
patent: WO 93/23391 (1993-11-01), None
patent: WO 94/14434 (1994-07-01), None
patent: WO 95/13266 (1995-05-01), None
patent: WO 98/05637 (1998-02-01), None
patent: WO 98/08818 (1998-03-01), None
patent: WO 99/43672 (1999-07-01), None
patent: WO 99/43651 (1999-09-01), None
patent: WO 99/43654 (1999-09-01), None
patent: WO 03/048122 (2003-06-01), None
patent: WO 2004/060878 (2004-07-01), None
patent: WO 2004/060878 (2004-07-01), None
patent: WO 2005/012238 (2005-02-01), None
patent: WO 2005023201 (2005-03-01), None
patent: WO 2005023201 (2005-03-01), None
patent: WO 2005058820 (2005-06-01), None
patent: WO 2006023611 (2006-03-01), None
patent: WO 2006/128142 (2006-11-01), None
Adediran et al., The Synthesis and Evaluation of Benzofuranones as .beta.-Lactamase Substrates, Bioorganic & Medicinal Chemistry, 9, 2001, pp. 1175-1183.
Bhatt et al., Nature Reviews, Drug Discovery vol. 2, 15-28, Jan. 2003.
Bonventure et al., et al., Nature 1997, 390: 622-625.
Burch et al., Proc. Natl. Acad. Sci. U.S.A., 84:6374-6378 (1989).
Chang et al, Biochem. Pharmacol., 36:2429-2436 (1987).
Chemical Abstract Service Registry No. 865200-20-0, “Benzoic acid, 4-[3-[5-chloro-1-(diphenylmethyl)-2-[2-[[[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]amino]ethyl]-1H-indol-3-yl]propyl]-(9CI),” 1 page (Oct. 13, 2005).
Smith, Biochem. J., 259:315-324 (1989).
Uozumi et al. Role of Cytosolic Phospholipase A2in Allergic Response and Parturition, Nature, 390:618-622, (Dec. 11, 1997).
Wasserman, Hospital Practice, 15:49-58 (1988).
Xi et al., Functionalized Deep-Cavity Cavitands, J. Org. Chem. 1999, 64, pp. 9286-9288.
Written Opinion of the International Searching Authority for PCT/US2006/020847, 7 pages (Nov. 20, 2006).
International Search Report for PCT/US2006/020847, 5 pages (Nov. 20, 2006).
Chung et al., Synthesis of 3-Fluoro-2-substituted amino-5,12-dihydro-5-oxobenzoxazolo[3,2-.alpha.] quinoline-6-carboxylic Acids Employing the Tandem Double Ring Closure Reaction of N-Acetyl-N-(2-hydroxyphenyl)anthranilic Acid as the Key Step, Tetrahedron vol. 51, No. 46, pp. 12549-12562, 1995, Elsevier Science Ltd, printed in Great Britain.
Clark et al., “Potential therapeutic uses of phospholipase A2inhibitors,”Expert Opin. Ther. Pat., 14:937-950 (2004).
Dennis, Drug Devel. Res., 10:205-220 (1987).
Dillard et al, Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A.sub.2. 1. Indole-3-acetamides, J. Med. Chem., 1996, vol. 39, No. 26, pp. 5119-5136.
Dillard et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A.sub.2. 2. Indole-3-acetamides with Additional Functionality, J. Med.chem. 1996, vol. 39, No. 26, pp. 5137-5158.
Doebel et al., J. Med. Chem., 1972, vol. 15, No. 10, pp. 1081-1082.
Draheim et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A.sub.2. 3 Indole-3-glyoxamides, J. Med. Chem 1996, vol. 39, No. 26, pp. 5159-5175.
Goodman et al., Self-Assembling, Chromogenic Receptors for the Recognition of Dicarboxylic Acid, J. Am. Chem. Soc., 1995, 117, pp. 8447-8455.
Jackson et al., Nature Reviews, Drug Discovery vol. 2, 1-15, Oct. 2003.
Kando et al, Biochem. Biophys. Res. Comm., 163:42-48 (1989).
Kramer et al, J. Biol. Chem., 264:5768-5775 (1989).
Langer et al., Synthesis of High-specific-radioactivity 4- and 6-[.sup.18F]fluorometaraminol- PET Tracers for the Adrenergic Nervous System of the Heart, Bioorganic & Medicinal Chemistry, 9, 2001, pp. 677-694.
Leslie et al, Biochem. Biophys. Acta., 963:476-492 (1988).
Nieswandt et al., J. Thrombosis and Haemostasis, 3: 1725-1736 (2005).
Roy et al., Further Studies on Anti-Inflammatory Activity of Two Potent Indan-1-Acetic Acids, Ind. J. Physiol. Pharmac., Jul.-Sep. 1982, vol. 28, No. 3, pp. 207-214.
Samuelson et al., Science, 237:1171-76 (1987).
Schevitz et al., Nature Structural Biology, vol. 2, No. 2, Jun. 1995, pp. 458-465.
Seilhamer et al, J. Biol. Chem., 264:5335-5338 (1989).
Behnke Mark L.
Chen Lihren
Clark James D.
Clerin Valerie
Hu Baihua
Fish & Richardson P.C.
Nwaonicha Chukwuma O
Sullivan Daniel M
Wyeth
LandOfFree
Methods for the use of inhibitors of cytosolic phospholipase A2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the use of inhibitors of cytosolic phospholipase A2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the use of inhibitors of cytosolic phospholipase A2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4108374